以下是Fred Turner的故事的中文翻译： Curative的联合创始人兼首席执行官Fred Turner分享了一段非凡的创业历程，其特点是戏剧性的转型和快速扩张，如今已发展成为一家估值达13亿美元的健康保险公司。他的故事始于英国，19岁时他意识到硅谷为年轻创始人提供了独特的环境，这与他在本国发现的注重资历的投资格局截然不同。 特纳的第一个创业项目TL Biolabs（后更名为Shield），最初专注于对奶牛和肉牛进行基因测序以预测其性状。尽管从Andreessen获得了种子资金，但有限的“奶牛潜在市场”（cow TAM）迫使他们转向人类诊断领域，先是提供家用性病检测，随后是败血症检测。尽管技术前景广阔，但这家败血症公司最终失败了，原因是一位战略性B轮投资者因竞争担忧而撤资。特纳将这次失败视为宝贵的学习经验，这使得他第二次创业变得更容易。不过，他幽默地提到，由于时机问题，他们以15万美元的价格出售了一项关键的实验室许可证，却在五个月后以2700万美元的价格又购买了一个类似的许可证。 2019年末，特纳创立了Curative，最初的重点是通过在现有设施内设立“迷你医院”来彻底改变败血症治疗。然而，迅速蔓延的COVID-19疫情迅速改变了他们的方向。由于他们的首席科学官已经开发出了一种新冠检测方法，Curative进行了彻底转型。从零开始，到2020年12月，该公司已能每天检测20.6万人，并在短短九个月内将员工数量从7人增至7000人。这得益于其“正交供应链”策略，即通过采购非常规材料来避免现有瓶颈。Curative在三年内创造了约50亿美元的收入，成为最大的非LabCorp/Quest检测服务提供商。尽管在疫情高峰期盈利，但高昂的固定成本意味着在疫情平稳期则会亏损。他们还管理了250万剂疫苗接种，这是一项“糟糕的业务”，由于政府报销不足而亏损，但他们将其作为对合作伙伴的服务而承担。 特纳始终意识到新冠疫情带来的繁荣是暂时的，Curative在2020年中期便开始规划其下一个篇章。在探索了实验室检测和医院收购之后，特纳意识到在美国医疗体系中，支付方（健康保险公司）才拥有真正的影响力。他们将约5亿美元的新冠疫情利润投资于建立一家新的健康保险公司。特纳指出，美国医疗体系效率低下，支付方和提供方之间的整合导致成本虚高和谈判劣势，他希望小型实体之间能有更多竞争。 自转向健康保险以来，一个重要的发现是人工智能的变革性力量。特纳承认，他们刚开始时并未预见到当前大型语言模型（LLMs）的浪潮。人工智能现在正在从根本上重塑他们的运营： * **资质认证：** 由Claude驱动的AI代理将医生资质认证的时间从2-3个月和50美元缩短到12小时和20美分。 * **承保：** 模型编写Python脚本来规范化各种传入的数据格式（PDF、电子表格），取代了人工操作。 * **网络合同：** 一个名为“Gwen”的AI代理负责供应商合同的邮件谈判，将合同产出从每周100份（由45名员工完成）提高到八周内3500份，而成本仅是人工的一小部分（每份合同70美元，而人工为1500-2000美元）。这使得人类团队能够专注于更大、更复杂、更注重关系的交易。 特纳坚信，在许多用例中，“SaaS已死”，他提到Curative计划今年削减80%的SaaS开支，其中包括一个价值60万美元的Salesforce合同，该合同被一个在两个月内构建的内部“vibe-coded”（内部开发）解决方案所取代。他预测，像Anthropic这样的人工智能模型可能成为10万亿美元的公司，即使价格上涨五倍，其带来的巨大效率提升也不会阻止人们使用它们。尽管承认后台岗位可能出现就业替代，但他认为“代理主管”等新角色将会出现，人类将专注于技术技能和人际关系建设。 除了Curative，特纳还与妻子共同创立了Subcritical，一家核裂变公司。他认为核能是安全且可扩展的，主要的挑战是监管障碍而非工程技术。Subcritical的“能量放大器”设计在亚临界状态下运行，具有固有的安全优势。 特纳的个人理念包括投资于他认识的人，并寻求多元化的视角来解决问题。他幽默地回忆说，在与他现在的妻子第二次约会之前，他分享了基因组文件以确保兼容性。他建议尽早要孩子，认为精力和睡眠不足是为人父母的理想状态。

Fred Turner, co-founder and CEO of Curative, shares an extraordinary entrepreneurial journey marked by dramatic pivots and rapid scaling, now culminating in a health insurance provider valued at $1.3 billion. His story begins in the UK, where he, at 19, realized Silicon Valley offered a unique environment for young founders, unlike the credential-focused investment landscape he found at home. Turner's first venture, TL Biolabs (later Shield), initially focused on sequencing dairy and beef cows for trait prediction. Despite raising seed funding from Andreessen, the limited "cow TAM" forced a pivot into human diagnostics, first with at-home STD testing and then into sepsis detection. Despite promising technology, the sepsis company ultimately failed when a strategic Series B investor pulled out due to competitive concerns. Turner reflects on this failure as a valuable learning experience, making it easier to build a company the second time around, though he humorously notes selling a crucial lab license for $150,000 only to buy a similar one for $27 million five months later due to timing. In late 2019, Turner started Curative with an initial focus on revolutionizing sepsis treatment through mini-hospitals within existing facilities. However, the burgeoning COVID-19 pandemic quickly shifted their course. With a COVID test already developed by their chief scientific officer, Curative pivoted entirely. From a starting point of zero, the company scaled to test 206,000 people in a single day by December 2020 and grew from 7 to 7,000 employees in just nine months. This was fueled by an "orthogonal supply chain" strategy, which avoided existing bottlenecks by sourcing unconventional materials. Curative generated approximately $5 billion in revenue over three years, becoming the largest non-LabCorp/Quest testing provider. While profitable during surges, the high fixed costs meant losing money during pandemic lulls. They also administered 2.5 million vaccinations, a "terrible business" that lost money due to insufficient government reimbursement, but was undertaken as a service to partners. Always aware of the temporary nature of the COVID boom, Curative began planning its next chapter in mid-2020. After exploring lab testing and hospital acquisitions, Turner realized that the payer (health insurance companies) held the true leverage in the US healthcare system. They invested about $500 million of their COVID profits into building a new health insurance company. Turner notes the inefficiency of the US system, where consolidation among both payers and providers leads to inflated costs and poor negotiation dynamics, wishing for more competition among smaller entities. A significant revelation since pivoting to health insurance has been the transformative power of AI. Turner admits they didn't foresee the current wave of LLMs when they started. AI is now fundamentally reshaping their operations: * **Credentialing:** An AI agent powered by Claude reduced the time to credential a doctor from 2-3 months and $50 to 12 hours and 20 cents. * **Underwriting:** Models write Python scripts to normalize diverse incoming data formats (PDFs, spreadsheets), replacing manual labor. * **Network Contracting:** An AI agent named "Gwen" handles email negotiations for provider contracts, increasing output from 100 contracts per week (by 45 staff) to 3,500 in eight weeks, at a fraction of the cost ($70 vs $1500-2000 per contract). This frees the human team to focus on larger, more complex, relationship-driven deals. Turner emphatically believes "SaaS is dead" for many use cases, citing Curative's plan to cut 80% of its SaaS spend this year, including a $600,000 Salesforce contract replaced by an internal "vibe-coded" solution built in two months. He projects that AI models like Anthropic could become $10 trillion companies, and even a 5x price increase wouldn't deter their usage due to the sheer efficiency gains. While acknowledging potential job displacement in back-office roles, he believes new roles like "agent supervisor" will emerge, and humans will focus on technical skills and relationship-building. Beyond Curative, Turner has co-founded Subcritical, a nuclear fission company with his wife. He sees nuclear energy as safe and scalable, with regulatory hurdles, not engineering, being the primary challenge. Subcritical's "energy amplifier" design, operating below criticality, offers inherent safety advantages. Turner's personal philosophy includes investing in people he knows and seeking diverse perspectives to solve problems. He humorously recounts sharing genome files with his now-wife before their second date to ensure compatibility. He advises having children early, citing the energy and lack of sleep as ideal conditions for parenthood.